Aptevo Therapeutics Inc. Reports 21% of Frontline AML Patients in Mipletamig Combination Study Advanced to Stem Cell Transplant
Aptevo Therapeutics Inc. announced that ten patients with newly diagnosed acute myeloid leukemia (AML) have advanced to allogeneic stem cell transplant following treatment with mipletamig in combination with venetoclax and azacitidine. Specifically, ten of 47 (21%) evaluable fron